HAYA Therapeutics begins dosing in Phase 1 trial for new heart failure therapy

HAYA Therapeutics announced that the first cohort has been fully enrolled and dosed in its Phase 1 clinical trial of HTX-001, an investigational antisense oligonucleotide that targets the WISPER long non-coding RNA, according to the company. The molecule is designed to downregulate WISPER in cardiac myofibroblasts to promote cell-state reprogramming away from a fibrotic phenotype; […] The post HAYA Therapeutics begins dosing in Phase 1 trial for new heart failure therapy appeared first on Longevity.Technology.